This study assessed the effects of supplementation with honey from Mimosa quadrivalvis L. (malícia) (MH) produced by jandaíra stingless bees (Melipona subnitida D.) on the lipid metabolism, antioxidant status and some intestinal health parameters of rats with diet-induced dyslipidaemia. Rats were randomly divided into four groups: healthy control (HC), dyslipidaemic control (DC), healthy experimental (EHH) and dyslipidaemic experimental (EDH). Malícia honey (MH) was administered (1000 mL kg-1) via orogastric feeding for 35 days. Dyslipidaemic rats supplemented with MH showed lower food consumption, increased glucose tolerance and superoxide dismutase (SOD) activity, and decreased total cholesterol, LDL and AST blood levels. Counts of Bifidobacterium spp. and Lactobacillus spp. and excretion of organic acids in faeces increased in dyslipidaemic rats supplemented with MH. MH supplementation protected the colon and liver from tissue damage induced by the dyslipidaemic diet. These results show the beneficial effects of MH on the lipid metabolism, antioxidant status and intestinal health of rats with diet-induced dyslipidaemia.

Scientists are working to identify prevention/treatment methods and clinical outcomes of Coronavirus Disease 2019 (COVID-19). Nutritional status and diet have a major impact on the COVID-19 health-disease process, mainly due to the bidirectional interaction between gut-lung axis. Individuals with inadequate nutritional status have a pre-existing imbalance in the gut microbiota and immunity as seen in obesity, diabetes, hypertension, or other chronic diseases. Communication between the gut microbiota and lungs or other organs and systems may trigger worse clinical outcomes in viral respiratory infections. Thus, this review addresses new insights into the use of probiotics and prebiotics as a preventive nutritional strategy in managing respiratory infections such as COVID-19 and highlighting their anti-inflammatory effects against the main signs and symptoms associated with COVID-19. The search for studies was performed through Pubmed, Cochrane Library, Scopus, and Web of Science databases; relevant clinical articles were included. Significant randomized clinical trials suggest that specific probiotics and/or prebiotics reduce diarrhoea, abdominal pain, vomiting, headache, cough, sore throat, fever, and viral infection complications such as acute respiratory distress syndrome. These beneficial effects are linked with modulation of the microbiota, products of microbial metabolism with antiviral activity, and immune regulatory properties of specific probiotics and prebiotics through of Treg cell production and function. There is a need to conduct clinical and pre-clinical trials to assess the effect of consuming these components together with the current therapies in COVID-19.

No abstract

No abstract